Document:

Exhibit 4.3

Bellon S.A.

Mr Michel Landel

Montigny le Bretonneux,

  September 13, 2005

 Dear Mr Landel,

You entered into the Group's service on September 1, 1984 and
    since then you have carried out a variety of duties, your employment contract
    being, whenever necessary, transferred from one company to another with your
    service record maintained. You have held a variety of corporate offices within
    our subsidiaries; in particular, since June 12, 2003, you have been Chief
    Operating Officer of Sodexho Alliance.

The purpose of this letter is to confirm to you the above history
    of your employment contract and the terms and conditions applicable to you
    from September 1, 2005.

The present letter cancels and replaces all previous contracts
    and/or agreements between you and our Company, or Sodexho Alliance or any
    subsidiary of Sodexho Alliance.

1. SERVICE RECORD

For the purpose of assessing the related rights, your service
    record will be regarded as running from September 1, 1984, the date on which
    you joined the Sodexho Group.

2. LOCATION AND MOBILITY

You will carry out your duties at the premises of Sodexho Alliance
    at Montigny le Bretonneux (France), on the understanding that the nature
    of your duties involves frequent travel, both in France and abroad.

3. COMPENSATION

3.1. Basic salary

You will receive guaranteed gross monthly basic salary of (euro)49,725
    (forty-nine thousand seven hundred and twenty five euros).

3.2. 13th month

You will receive, in addition, a 13th month bonus paid in December,
    calculated on the basis of your most recent guaranteed monthly gross salary,
    and in proportion to your presence during the year in question. 

 3.3. International travel allowance

In consideration of your business-related travel you will receive
    a daily international travel allowance, the terms of which will be set each
    year by separate rider. For 2005, taking into account the anticipated number
    of days' foreign travel, the monthly advance payment relating to said allowance
    will be (euro)12,800 gross (twelve thousand eight hundred euros gross).

3.4. Performance-related bonus

You will receive each year after approval of the financial
    statements a performance-related bonus of between 0% and 100% of the compensation
    you have actually received during the year (basic salary, 13th month, international
    travel allowance). Said bonus will be allocated on the basis of your achievements
    during the year relative to the targets set for you and in proportion to
    your presence during the year in question.

4. WORKING HOURS

Because of the nature of your duties as managing executives,
    the working hours regulations do not apply to you.

5. SUPPLEMENTARY WELFARE BENEFITS

You will be affiliated to Axa Assurances as regards supplementary
    welfare benefits and to Uniprevoyance as regards top-up reimbursement of
    medical expenses on the usual Company terms. 

 You agree to comply with the health risk prevention policy
    applicable to Sodexho Group managers. 

6. PENSION 

You will be affiliated to the Mederic Group (CIPC, CIPS) pension
    fund at 21 rue Laffitte, 75317 Paris Cedex 09 as regards top-up pension schemes
    on the usual Company terms. In addition, you will be covered by the top-up retirement
    plan for Sodexho Group managing executives. 

7. COMPANY CAR

You will have use of a Company car on terms dictated by company
    policy on the matter. Your use of such vehicle for your personal needs will be
    declared as a benefit in kind in accordance with the applicable law. 

 

8. CONFIDENTIALITY

During the term of the contract and on fulfilling your duties
    you will have access to information and data relating to the company (in
    particular and non-exhaustively: its policy, strategies, methods, etc) which
    will be communicated to you orally or in writing on all types of media. 

All such information will be deemed confidential, and you agree
    during the term of the contract and on expiration thereof that said information
    will be protected and kept strictly confidential and only disclosed internally
    to Sodexho personnel on a need-to-know basis. 

All information and copies thereof will remain the property
    of Sodexho Alliance and related companies, and must be returned to it immediately
    on demand. 

9. NON COMPETITION 

If you leave our Company at whatever time and for whatever
    reason, given the nature of your duties, you agree not to provide your services
    to any company liable to compete with the Sodexho Group in any way in any
    business or country in which you have been involved in the two years preceding
    your departure. Such prohibition applies also to your participation in any
    capacity in creating such an enterprise and to your taking a stake therein
    whether directly or indirectly. 

The present non-competition clause will be limited as regards
    yourself to a period of three years from your departure. 

In consideration of the present clause, you will receive a
    bonus equal to 1x your total gross annual salary (basic salary, 13th month,
    international travel allowance and most recent performance-related bonus),
    payable to you in installments on the following basis:

  - 50% on your departure,

    - 50% at the end of the three years.

The payments will be made only on production, at each installment
    date, of a document attesting to the identity and business of your new employer. 

In the event of termination of the present contract at the
    initiative of the Company for serious or gross misconduct, we reserve the
    right to release you from the effects of this clause, thereby rendering null
    and void and without object the specified financial consideration, in which
    case you will be informed by the Company at the time of your effective departure
    from the Company. 

 Any breach of the prohibition on competition, while releasing
    the Company from the requirement to pay the financial consideration, would
    render you liable to reimburse the Company whatever you had already received
    in this respect. In addition, you would become automatically liable to pay
    a penalty hereby fixed at three times your total gross annual salary with
    no need to give formal notice to cease the competing business and without
    prejudicing any proceedings that the Company expressly reserves the right
    to institute for damages for the loss suffered and to secure a court order
    with penalties to cease the competing business. 

 

 10. TERM OF THE CONTRACT AND TERMINATION

The present contract is concluded for an indefinite period.
    It may be ended at the initiative of either party subject to six months'
    notice. 

If the present contract of employment is terminated at the
    initiative of the Company for whatever reason (saving serious or gross misconduct
    on your part) and at whatever date, termination compensation of two years'
    total salary (basic salary, 13th month, international travel allowance and
    most recent performance-related bonus) will be payable to you. It is stipulated
    that such termination compensation will be paid over and above the redundancy
    compensation payable to you under the collective agreement or by law if you
    are made redundant under such circumstances. 

The principle and amount of such termination compensation are
    set in the light of your level of responsibility and the difficulties you
    would experience in finding alternative employment if your contract of employment
    were terminated by us. 

11. APPLICABLE COLLECTIVE AGREEMENT 

This contract is additionally governed by the National Collective
    Agreement of Contract Catering Enterprises and by the agreement on Flexible
    Working Hours signed by the employers' association of the Sodexho Group on
    March 13, 2000. 

For the record, I would ask you to kindly return to me the
    bottom copy of this letter signed by you and preceded by the words "read
    and approved".

Yours faithfully, 

	Sophie Clamens	Michel Landel 
	Chairman of the Management Board 	 
	 	 
	Copy: Payroll - Group Human Resources 	 

  

 

 Bellon S.A. 

Mr Michel Landel

Montigny, September 1, 2005

RIDER TO YOUR CONTRACT OF EMPLOYMENT

Dear Mr Landel,

Because you perform on our behalf prospection, development
    or audit assignments abroad or in the French Overseas Territories, you will
    receive a daily international travel allowance, the terms of which applicable
    from September 1, 2005 are as follows: 

The amount of such allowance is set at 1,600 euros. It will
    be paid to you for each calendar day spent on assignment abroad, except for
    days relating to periodic meetings of an institutional nature or to internal
    information or training meetings. 

Solely for the purposes of calculating this allowance, the
    total number of days abroad is capped at 32 days from September 1, 2005 through
    December 31, 2005. Based on your foreign travel diary, you will receive a
    monthly advance payment of 12,800 euros over four months. 

In order to justify such advance payment, please supply the
    necessary items to our Payroll department in December, and in particular
    a statement of the exact number of days when you will be on assignment abroad.
    On consideration of such statement, an adjustment may be made to your December
    salary. In addition, since such allowances are non-taxable, you agree to
    retain supporting vouchers for the travel concerned for possible production
    to the tax authorities. 

Finally, we confirm that said allowance is included in the
    contributions base securing your social security cover. 

For the record, I would ask you to kindly return to me the
    bottom copy of this letter signed by you and preceded by the words "read
    and approved".

Yours faithfully,

	Sophie Clamens	Michel Landel 
	Chairman of the Management Board 	 
	 	 
	Copy: Payroll - Group Human ResourcesAmendment to Asset Purchase Agreement

    Exhibit
      10.1

    

    AMENDMENT

    

    This
      Amendment is
      made as of January 8, 2007 by and among DFB Biotech, Inc. a Delaware corporation
      (“Buyer”),
      and
      BioSpecifics Technologies Corp., a Delaware corporation (“BTC”),
      and its
      wholly-owned subsidiary Advance Biofactures Corporation, a New York corporation
      (“ABC”)
      (BTC and ABC
      each being hereinafter individually, and collectively where applicable, referred
      to as “Seller”).
      (Buyer and
      Seller are at times referred to herein collectively as the “Parties.”)

     

    RECITALS

     

    Whereas
      the Parties
      entered into an Asset Purchase Agreement dated March 3, 2006 (the “APA”);
      and

     

    Whereas
      the Parties
      now desire to amend the APA as detailed herein to clarify certain provisions
      of
      the APA in light of subsequent events;

     

    AGREEMENT

     

    Now,
      therefore, in
      consideration of the premises and mutual covenants herein contained as well
      as
      other good and valuable consideration, the receipt and adequacy of which are
      hereby acknowledged, the Parties intending to be legally bound agree as
      follows:

     

    
      	
              1.

            	
              Any
                capitalized term in this Amendment not defined herein shall have
                the same
                meaning as set forth in the APA.

            

    

     

    
      	
              2.

            	
              The
                following
                definitions shall be added as defined terms to Section 1.1 of the
                APA:

            

    

     

    “‘Auxilium’
      - shall mean
      Auxilium Pharmaceuticals, Inc., the Delaware corporation which is a party to
      the
      Auxilium License (as defined below).”

     

    “‘Retained
      API’
      - shall mean
      collagenase, excluding collagenase for dermal formulations labeled for topical
      administration, OMITTED AND FILED SEPARATELY WITH THE SECURITIES &
EXCHANGE COMMISSION.”

     

    “Transferred
      API’
      - shall mean
      collagenase, including but not limited to collagenase for dermal formulations
      labeled for topical administration, which is the active pharmaceutical
      ingredient of the Product, OMITTED AND FILED SEPARATELY WITH THE
      SECURITIES & EXCHANGE COMMISSION.”

     

    “‘Auxilium
      License’ -
      shall mean the
      Development and License Agreement by and between BTC and its Affiliates (as
      defined therein) and Auxilium, dated June 3, 2004, as amended May 10,
      2005.”

     

    “‘Auxilium
      Product’
      - shall mean
      pharmaceutical products, excluding all dermal formulations labeled for topical
      administration, which contain Retained API as an active
      ingredient.”

     

    “‘Competing
      Product’
      - shall mean a
      product that contains Retained API as an active ingredient and is sold in a
      country by a party (other than Auxilium its Affiliates or Sublicensees as
      defined in the Auxilium License) for

    
       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      an
        indication when
        Auxilium, its Afilliates or Sublicensees also markets an Auxilium Product
        approved for such indication in such country.”

       

    

    “‘Retained
      Cell Banks’
      - shall mean the
      cell banks of Seller as of the Closing Date, which are listed in Schedule
      1.1(h).”

     

    “‘Transferred
      Cell Banks’
      - shall mean the
      cell banks of Seller as of the Closing Date, which are listed in Schedule
      1.1(d).”

     

    
      	
              3.

            	
              Each
                definition below shall be deleted in its entirety from Section 1.1
                of the
                APA and replaced with the
                following:

            

    

     

    “‘API’
      - shall mean
      collagenase, which is the active pharmaceutical ingredient for the Product,
      obtained from fermentation of Clostridium.”

     

    “‘Overlap
      Intangible Assets’ -
      means the
      intangible assets (including Records relating to the Transferred API and
      Transferred Cell Banks) owned or licensed by ABC or BTC not solely related
      to
      topical uses and indications for collagenase, which are used in the research,
      development, use, commercialization, manufacture, sale or distribution of the
      Product, Retained and Transferred API, including those set forth in Schedule
      1.1(b).”

     

    “‘Product’ -
      means the
      collagenase ointment manufactured by Seller and marketed by Abbott Laboratories
      under the trademark SANTYL as successor to Knoll Pharmaceutical Company pursuant
      to the Knoll License Agreement, as well as all components of the SANTYL
      collagenase ointment including but not limited to the Transferred API but
      excluding the Retained API.”

     

    “‘Purchased
      Assets’ -
      means:

     

    (a)  to
      the extent
      exclusively related to or used in connection with the API, the Product, or
      Seller’s Topical Business, all items of inventory of the Seller and ABC-C,
      wherever located, including all finished goods, work in process, raw materials,
      spare parts, and all other related materials and supplies and listed on
Schedule
      1.1(c) (collectively
      the
“Purchased
      Inventories”);

     

    (b)  (i)
      the ELA, the
      Product, and the Transferred API; and (ii) all Records of Seller relating to
      the
      ELA, the Product, or related solely to the Transferred API; 

     

    (c)  the
      Transferred
      Cell Banks; 

     

    (d)  the
      ABC-C Shares;

     

    (e)  all
      the equipment
      and materials owned by BTC or ABC, located in the Lynbrook, New York or Curaçao
      facilities, which are used exclusively in Seller’s Topical Business and listed
      in Schedule
      1.1(e);

     

    (f)  the
      Knoll License
      Agreement and the Tufts License Agreement and all Intellectual Property
      thereunder; 

     

    (g)  all
      Contracts
      relating solely to Seller’s Topical Business to which Seller or ABC-C is a party
      and listed in Schedule
      1.1(f) (the
“Seller
      Contracts”);

     

    (h)  to
      the extent
      related to the Transferred Employees, all personnel Records and other Records
      that Seller is not required by law to retain in its possession; 

     

    (i)  except
      as provided
      in Section 7.14(a) , all Intellectual Property owned or controlled by Seller
      or
      ABC-C

    
       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      relating
        solely to
        (i) Seller’s Topical Business, (ii) the Product, (iii) the Transferred API, (iv)
        the ELA, or (v) topical uses and indications for collagenase, all as listed
        on
Schedule
        1.1(g),
        (collectively the
“Intellectual
        Property Assets”);

       

    

    (j)  all
      clinical and
      other data, reports and communications to the extent solely related to topical
      indications and uses for collagenase or Seller’s Topical Business; and

     

    (k)  all
      governmental
      authorizations and pending applications therefor, and registrations, to the
      extent assignable, to the extent solely related to topical uses and indications
      for collagenase or Seller’s Topical Business.”

     

    “‘Seller
      Injectable Assets’ -
      means any
      tangible or intangible assets (including, patents, trademarks, copyrights,
      or
      other Intellectual Property asset, equipment, inventory, Contract or other
      asset) owned, licensed or leased prior to the Closing Date by Seller, or any
      Affiliate of Seller, relating to the research, development, use,
      commercialization, manufacture, sale or distribution of the Auxilium Product,
      and set forth in Schedule
      1.1(h).”

     

    
      	
              4.

            	
              Section
                2.1(b) of the APA shall be deleted in its entirety and replaced with
                the
                following:

            

    

     

    “(b)  Overlap
      Intangible Assets.
      Upon the terms
      and subject to the conditions set forth herein, at the Closing, but effective
      as
      of the Effective Time, Seller shall exclusively (even as to Seller),
      perpetually, without royalty, and irrevocably license to Buyer the right to
      use
      the Overlap Intangible Assets for the research, development, use,
      commercialization, manufacture, marketing, and sale of topical products, free
      and clear of any Encumbrances, and Buyer shall accept such license from Seller
      of, the Overlap Intangible Assets.”

     

    
      	
              5.

            	
              The
                following
                shall be added to the APA as Section
                2.2(o):

            

    

     

    “(o).  any
      drug master
      file owned by Seller, its Affiliates or sublicensees, including Auxilium. For
      purposes of clarity, the Parties agree that the ELA is not, nor shall it be
      construed to be, a drug master file.”

     

    
      	
              6.

            	
              Section
                7.7(a) of the APA shall be deleted in its entirety and replaced with
                the
                following:

            

    

     

    OMITTED
      AND
      FILED

    SEPARATELY
      WITH THE

    SECURITIES
      & EXCHANGE COMMISSION

    

    
      	
              7.

            	
              Section
                7.15
                of the APA shall be deleted in its entirety and replaced with the
                following:

            

    

     

    “7.15  Maintenance
      and Defense of Overlap Intangible Assets

     

    Seller
      agrees that
      all patents and other Intellectual Property included within the definition
      of
      Overlap Intangible Assets shall be maintained
      and defended in
      all relevant jurisdictions throughout the OMITTED
      AND
      FILED SEPARATELY WITH THE SECURITIES & EXCHANGE
      COMMISSION.
      Upon OMITTED
      AND
      FILED SEPARATELY WITH THE SECURITIES & EXCHANGE
      COMMISSION,
      if a decision is
      made not to defend or maintain any such patent or other Intellectual Property,
      then Seller agrees that Buyer may maintain or defend 

     

    
      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      such
        patent or
        other Intellectual Property and Seller shall provide, at Buyer’s expense, all
        reasonable assistance requested by Buyer related to such maintenance or
        defense.”

      
      

    

     

    
      	
              8.

            	
              The
                following
                shall be added to the APA as Section
                7.18:

            

    

     

    “7.18  Buyer
      Acknowledgment of Auxilium License

     

    To
      the extent
Records
      included in
      the Purchased Assets are subject to the Auxilium License, Buyer acknowledges
      that Auxilium may have limited rights
      to such Records.
      Therefore upon Auxilium’s reasonable written request
      and provided that
      such Records are in Buyer’s actual possession,
      Buyer will grant
      Auxilium a
limited
      right to
      access, cross-reference, and use (at Auxilium’s sole cost and expense) such
      Records
      to the extent (a)
      they are subject to the Auxilium License and (b) they are reasonably
      required
      in regulatory filings for the Auxilium Product.”

     

    
      
        	
                9.

              	
                The
                  following
                  shall be added to the APA as Section
                  7.19:

              

      

       

    

    OMITTED
      AND
      FILED

    SEPARATELY
      WITH THE

    SECURITIES
      & EXCHANGE COMMISSION

    

    
      	
              10.

            	
              The
                references to “API” in Schedule 1.1(b) and Schedule 1.1(g) shall be
                amended to refer to “Transferred
                API.”

            

    

     

    
      
        	
                11.

              	
                Except
                  as
                  expressly amended or modified hereby the APA shall remain in full
                  force
                  and effect in accordance with its original
                  terms.

              

      

       

    

     

    [Remainder
      of
      page intentionally left blank]

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS
      WHEREOF, the
      Parties have
      caused this Amendment to be executed in triplicate originals as of the date
      and
      year first above written.

     

    

      
        	
                SELLER:

                 

              	 	 
	
                BioSpecifics
                  Technologies Corp.

                 

                 

              	 	Advance
                Biofactures Corporation
	
                By:

              	
                /s/
                  Thomas
                  Wegman

              	 	
                By:

              	
                /s/
                  Thomas
                  Wegman

              
	 	
                Name:
                  Thomas
                  Wegman

              	 	 	
                Name:
                  Thomas
                  Wegman

              
	 	
                Title:
                  President

                 

                 

              	 	 	
                Title:
                  President

                 

              
	 	 	 	 	 
	
                BUYER:

                 

              	 	 	 
	
                DFB
                  Biotech, Inc.

                 

                 

              	 	 	 
	
                By:

              	
                /s/
                  Paul
                  Dorman

              	 	 	 
	 	
                Name:____________________________________

              	 	 	 
	 	
                Title:______________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]